PolyMed: Can Cardiology, New Devices and International Expansion Power 100% Revenue Growth by FY30?

PolyMed has set an ambitious goal to double its revenue by FY30, starting from a base of Rs 1,875 crore in FY26. To achieve this, the company plans to drive growth through its core cardiology business, the launch of new high-technology devices, and expansion into international markets. It also aims to support this scale-up by leveraging new manufacturing capacity and pursuing strategic acquisitions.

For investors, this target highlights a significant growth opportunity for the company, provided it can execute its strategy effectively. However, achieving this 100% revenue growth will not be without hurdles. Key risks include navigating complex regulatory timelines, managing geopolitical uncertainties, and mitigating rising logistics costs. Additionally, the company must address its weakness in the renal segment to ensure balanced growth across its portfolio.

Moving forward, investors should closely monitor PolyMed's progress in launching new products, its success in international markets, and its ability to manage operational challenges. The company's ability to navigate these risks will be critical in determining whether it can meet its ambitious growth targets.